Timeline of Federal Funding SARS
Timeline of Federal Funding SARS
We noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003
they sought to patent the SARS coronavirus that had reportedly transferred to humans
during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature.
This legality did not deter CDC in their efforts. Their application, updated in 2007,
ultimately issued as U.S. Patent 7,776,521 and constrained anyone not licensed by their
patent from developing tests or kits to measure SARS coronavirus in humans. Work
associated with this virus by their select collaborators included considerable amounts of
chimeric engineering, gain-of-function studies, viral characterization, detection,
treatment (both vaccine and therapeutic intervention), and weaponization inquiries.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of
millions of dollars of U.S. research grants from several federal agencies but also sat on
the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV)
and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible
for determining “novelty” of clades of virus species but directly benefitted from
determining declarations of novelty in the form of new research funding authorizations
and associated patenting and commercial collaboration. Together with CDC, NIAID,
WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and
their several coronavirus patent holding biotech companies; Moderna; Ridgeback;
Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted
what we would suggest are “interlocking directorates” under U.S. anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board
(GPMB) whose members were instrumental in the Open Philanthropy-funded global
coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event,
funded by the principal investor in Sherlock Biosciences and linking interlocking funding
partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory
disease global preparedness exercise to be completed by September 2020 alerted us
September 8-16, 2020
1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for
Producing Recombinant Coronavirus” Filed 2002 and issued 2007 https://
patents.google.com/patent/US7279327B2/ru
1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on
coronavirus November 14, 2000 which was abandoned April 2010 making
it public domain.
2000 Ralph Baric AI23946 and GM63228 from the National Institutes of Health
actively working recombinant CoV.
2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the
patent on the RNA sequence) and 7,776,521 (the patent on the testing
methodology. These patents give the U.S. Department of Health and
September 8-16, 2020
With their patent filing, CDC enters the conspiracy to restrain interstate
trade. The ‘852 patent application was rejected as unpatentable but was
allowed in 2007 after having the rejection appealed and overturned
provided that the CDC “inventors” acknowledged that they provided an
enabling disclosure that placed the genome of SARS coronavirus in the
public domain prior to filing their patent application. 15 USC §1-3
Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s
Global Grand Challenges Scientific Advisory Board (served through 2010).
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and
patent US7,151,163 https://www.sbir.gov/node/305319
July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S.
Patent 7,618,802 which issued on November 17, 2009. https://
patents.google.com/patent/US7618802B2
At this conference, the term “The New Normal” was introduced by Merck
2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel
Hill (non-competitive grant from NIAID)
2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel
Hill (non-competitive grant from NIAID)
Patent issuance for SARS coronavirus patents peak post the Asia outbreak
at 391 issued patents.
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with
reference to the grant funding in https://molbio.mgh.harvard.edu/
szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel
Hill (non-competitive grant from NIAID)
“AD3C provided data from the Denison and Baric laboratories to Gilead,
and that led to clinical investigations.” Remdesivir, initially designed to
treat MERS was suggested to be effective in treating SARS. Whitley stated
that he was concerned that both MERS and SARS “not only could come
back, but be imported into the U.S.”
2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents
US9872900 and US10022435
2016 NIH through Scripps Institute and Dartmouth College file patent
application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and
their Use” disclosing mRNA technology that overlaps (and is used in
tandem with) Moderna’s technology. https://patents.google.com/
patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was
well known to Moderna as he’s the person at NIH that Moderna “e-
mailed” to get the sequence for SARS CoV-2 according to Moderna’s
report here (“In January 2020, once it was discovered that the infection in
Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr.
Barney Graham, deputy director of the Vaccine Research Center at the
National Institutes of Health, asking him to send the genetic sequence for
the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html
In addition, co-inventor Jason McLellan worked with Graham on a
vaccine patent jointly owned with the Chinese government filed in
Australia in 2013 https://patents.google.com/patent/AU2014231357A1/
en?inventor=Jason+MCLELLAN.
2017 August – Sanofi buys Protein Science Corp with considerable SARS patent
holdings
2018 June – Sanofi buys Ablynx with considerable SARS patent holdings
September – Fauci and Dr. Chris Elias sit on the Global Preparedness
Monitoring Board for the WHO stipulating the need to have a global
exercise on the accidental or intentional release of a respiratory
pathogen by September 2020. Violation of 15 USC § 19.
September 8-16, 2020
2020 February - Fauci, Baric, and others lament the absence of funding for
coronavirus research and highlight the need to have the public see the
gravity of their commercial interest.
“Scientists who have applied for funding to study coronaviruses say that
they feel more pressure to explain why their research is relevant after an
outbreak has ended. Those in the field knew that there was much more to
be gleaned about the coronaviruses that already circulate in humans —
and that a new coronavirus could start making people sick at any time.”
https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-
interest-hurt-coronavirus-research/
This statement was misleading as Dr. Baric’s lab had received million of
dollars of non-competitive awards from NIAID without the requirement to
“apply” for such funds.
Over 5000 patents and patent applications have included reference to SARS
Coronavirus dating back to priority dates of 1998. They are summarized below.
199 199 200 200 200 200 200 200 200 200 200 200 201 201 201 201 201 201 201 201 201 201 202 tota
8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 l
September 8-16, 2020
511
file 0 0 0 0 0 120 338 290 328 297 256 188 198 207 244 371 407 466 451 416 326 199 9 file
1
511
issue 0 0 0 0 0 1 63 135 179 224 275 334 391 61 8 314 431 420 504 513 449 578 231 issue
1
On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and
Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent 8,058,069. This
patent, owned by Arbutus Biopharma Corp (principally owned by Roivant Science Ltd),
covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the
core technology was based on work originally done at the University of British Columbia
and was first licensed in 1998.
Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal
Government must provide information regarding intellectual property infringement
issues as part of their contract. Under FAR §27.201-1(c) and (d), the Government both
requires a notice of infringement or potential infringement as well as retention of
economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the
“Contractor shall indemnify the Government and its officers, agents, and employees
against liability, including costs for infringement of any United States Patent…”. In
September 8-16, 2020
addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has
identified fourteen other issued patents preceding the ‘600 patent which were used by
patent examiners to limit patents arising from the same funded research including
patents sought by CureVac.
In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and
advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged
in illegal patent activity and demonstrated contempt for U.S. Patent law. To make
matters worse, the U.S. Government has given it financial backing in the face of
undisclosed infringement risks potentially contributing to the very infringement for which
they are indemnified.
Modrena’s U.S. Patent 10,702,600 and U.S. Patent 10,702,599 share reference to this
language:
Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to
other countries before brought under control. Because of a concern for reemergence
or a deliberate release of the SARS coronavirus, vaccine development was initiated
(emphasis added).
US10702600B1
http://patft.uspto.gov/netacgi/nph-Parser?
Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1
&f=G&l=50&s1=10702600.PN.&OS=PN/10702600&RS=PN/10702600
On March 28, 2019 (9 months before the SARS outbreak), Moderna altered a rejected
patent application in which they stated that vaccine development for SARS
coronavirus was initiated based on concern for a “deliberate release of SARS
coronavirus”. Since 2010, Moderna has known that other companies own the patent
on lipid nanoparticles (LNP) required to deliver the vaccine. Given Moderna’s over 130
cases of violating the law in their patent filing and given their executives’ stock sales,
September 8-16, 2020
there is reason to be concerned that Dr. Anthony Fauci is setting up President Trump for
a patent infringement injunction on the eve of the vaccine approval. Dr. Fauci has
been promoting a vaccine that clearly violates the Federal Acquisition Regulations and
he’s likely known it since the company’s IPO in 2018.
September 8-16, 2020
Mark Denison